Abstract:Abstract Background and objectives: Analysis of gene expression has identified various molecular subtypes. These molecular subtypes defined by immunohistochemistry expression of estrogen receptor (ER) or progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2) : luminal A, luminal B, basal cell-like and HER2-expresing. This study evaluates clinical and pathologic features and survival of the four molecular subtypes in premenopausal and postmenopausal women from northeast China. Methods: A retrospective analysis of 1214 women diagnosed with breast cancer from 2000 to 2007 in Breast Surgery Department, First Hospital of Jilin University. Four molecular breast cancer subtypes defined as: luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), basal-like (ER-, PR-, HER2-), and HER2-expresing, (ER-, PR-, and HER2+). We examined the prevalence of breast cancer subtypes and analyzed the associations with patient clinicopathologic features: age, menopausal status, tumor size, lymph node status, stage of cancer at diagnosis, histological characteristics, and breast cancer-specific survival. Results: Among the all cases, the luminal A subtype was the most prevalent in our study sample (56.0%) compared with basal -like (18.5%), luminal B (13.7%), and HER2-expresing subtypes (11.8%). The four molecular subtypes differed significantly by menopausal status (P=0.011), age (P<0.001) and lymph node status (P<0.001). Luminal A subtype was more likely to with Stage II breast cancer (P<0.001) and most present with size of 2.1-5 cm (P<0.001). The luminal B and the HER2-expresing subtypes presented an increased association with more aggressive clinical course when compared with others subtypes. The estimated median follow-up period for all subjects was 54 months (range, 1 month to 120 months). The 8-year overall survival for all patients was 81.3% (95%CI, 79.4-83.7) and disease-free survival was 77.8% (95% CI, 75.4-79.9). The Kaplan-Meier curve showed breast cancer-specific survival differed significantly among the molecular subtypes (P < 0.03), with the luminal B and HER2-expresing subtypes having the poorest outcome. Conclusion: Luminal A breast tumor appeared the better outcome than the others three subtypes and the shortest survival was HER2-expresing subtype. The poor clinical outcomes of luminal B subtype with women from northeast China were different from those of Western women could contribute to the poor prognosis of breast cancer observed in this cohort of patients and some of them couldn't accept molecular targeted therapy with trastuzumab by poor economic situations. Figure available in online version. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-12-08.

Characteristics and prognostic values of traditional pathological parameters and advanced molecular subtypes in women in Beijing with operable breast cancer: a retrospective analysis.

Incidence and Risk Factors of Lymph Node Metastasis in Breast Cancer Patients Without Preoperative Chemoradiotherapy and Neoadjuvant Therapy: Analysis of SEER Data.

Abstract P3-12-08: Molecular Breast Cancer Subtypes in Women from Northeast China: Eight-Year Retrospective Study about Clinicopathologic Features and Survival

Characteristics and prognosis for molecular breast cancer subtypes in Chinese women

The characteristics of breast cancer subtypes: implications for treatment guidelines and individualized treatment strategies in China.

Clinicopathological analysis of early-stage breast cancer patients that meet indications for <i>BRCA1/2</i> genetic testing

Clinicopathological Features and Survival of Early Stage Breast Cancer in Northwest China: A Population‐based Retrospective Study of 1287 Patients

Distinct Distribution and Prognostic Significance of Molecular Subtypes of Breast Cancer in Chinese Women: a Population-Based Cohort Study

HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer

Pathological features and prognosis of different molecular subtypes of breast cancer

Breast Cancer Subtypes and Survival in Chinese Women with Operable Primary Breast Cancer

Clinicopathological analysis of early-stage breast cancer patients that meet indications for BRCA1/2 genetic testing.

Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients.

Clinical Characteristics and Prognosis of Different Subtypes of Breast Cancer

Combination Impact Of Axillary Lymph Node Status And Biological Subtypes On Prognosis And Breast Conserving Surgery In Locally-Invasive Breast Cancer: A Real-World Study Of A Chinese Population

Molecular Subtype Approximated by Quantitative Estrogen Receptor, Progesterone Receptor and Her2 Can Predict the Prognosis of Breast Cancer

Clinical features and survival analysis of molecular subtyping of breast cancer

Clinical Pathologic Status and Expression of Tumor Markers in 5,000 Chinese Breast Cancers

Predictive Value Of Breast Cancer Molecular Subtypes In Chinese Patients With Four Or More Positive Nodes After Postmastectomy Radiotherapy

HER2-enriched tumors have the highest risk of local recurrence in Chinese patients treated with breast conservation therapy.

A retrospective analysis of clinicopathological characteristics and risk factors for recurrence in young patients with breast cancer